PDCD1 and esophageal squamous cell carcinoma: There is no standardized methodology for PD-L1 testing across currently indicated PD-1 therapies for ESCC, with testing methods varying regionally by local clinical practices, although there is a relatively high level of concordance between TAP score versus CPS (overall percentage agreement [OPA]: 90%) and TPS (OPA: 78%) (23).